awmsg logo

epoetin delta (Dynepo®)

Reference No. 129

Publication date:

Appraisal information

epoetin delta (Dynepo®) solution for injection

Company: Shire Pharmaceuticals Ltd
BNF category: Nutrition and blood
NMG meeting date: 16/01/2008
AWMSG meeting date: 14/02/2008
Submission Type: Full Submission
Status: Marketing authorisation withdrawn
Advice No: 0408
Ratification by Welsh Government: 06/03/2008

Current Progress

Ratification by
Welsh Government

AWMSG advice

LICENCE WITHDRAWN. Please refer to the European Medicines Agency website for further information. Epoetin delta (Dynepo®) is recommended for use in patients on dialysis (and in patients not on dialysis) within NHS Wales for the treatment of anaemia in patients with chronic renal failure. Epoetin delta (Dynepo®) should only be initiated by specialists experienced in the treatment of chronic renal failure. AWMSG are of the opinion that epoetin delta (Dynepo®) may be suitable for shared care agreements within NHS Wales. Existing shared care protocols for current erythropoietin stimulating agents (ESAs) may need to be reviewed in light of this decision.
Final Appraisal Recommendation (FAR)